283 related articles for article (PubMed ID: 18665773)
1. Attenuated influenza A viruses with modified cleavage sites in hemagglutinin as live vaccines.
Stech J
Expert Rev Vaccines; 2008 Aug; 7(6):739-43. PubMed ID: 18665773
[TBL] [Abstract][Full Text] [Related]
2. A new approach to an influenza live vaccine: modification of the cleavage site of hemagglutinin.
Stech J; Garn H; Wegmann M; Wagner R; Klenk HD
Nat Med; 2005 Jun; 11(6):683-9. PubMed ID: 15924146
[TBL] [Abstract][Full Text] [Related]
3. Phenotypic properties resulting from directed gene segment reassortment between wild-type A/Sydney/5/97 influenza virus and the live attenuated vaccine strain.
Parks CL; Latham T; Cahill A; O'neill RE; Passarotti CJ; Buonagurio DA; Bechert TM; D'Arco GA; Neumann G; Destefano J; Arendt HE; Obregon J; Shutyak L; Hamm S; Sidhu MS; Zamb TJ; Udem SA
Virology; 2007 Oct; 367(2):275-87. PubMed ID: 17599381
[TBL] [Abstract][Full Text] [Related]
4. Influenza B virus with modified hemagglutinin cleavage site as a novel attenuated live vaccine.
Stech J; Garn H; Herwig A; Stech O; Dauber B; Wolff T; Mettenleiter TC; Klenk HD
J Infect Dis; 2011 Nov; 204(10):1483-90. PubMed ID: 21917878
[TBL] [Abstract][Full Text] [Related]
5. The potential of a protease activation mutant of a highly pathogenic avian influenza virus for a pandemic live vaccine.
Gabriel G; Garn H; Wegmann M; Renz H; Herwig A; Klenk HD; Stech J
Vaccine; 2008 Feb; 26(7):956-65. PubMed ID: 18164519
[TBL] [Abstract][Full Text] [Related]
6. Seed viruses containing novel avian HA and NA antigens for prevention against potential influenza pandemic.
Li S; Perdue ML; Patzer E
Dev Biol (Basel); 2002; 110():135-41. PubMed ID: 12477316
[TBL] [Abstract][Full Text] [Related]
7. A new approach to an influenza life vaccine: haemagglutinin cleavage site mutants generated by reverse genetics.
Stech J; Klenk HD
Berl Munch Tierarztl Wochenschr; 2006; 119(3-4):186-91. PubMed ID: 16573209
[TBL] [Abstract][Full Text] [Related]
8. Protection of chickens against H5N1 highly pathogenic avian influenza virus infection by live vaccination with infectious laryngotracheitis virus recombinants expressing H5 hemagglutinin and N1 neuraminidase.
Pavlova SP; Veits J; Keil GM; Mettenleiter TC; Fuchs W
Vaccine; 2009 Jan; 27(5):773-85. PubMed ID: 19041677
[TBL] [Abstract][Full Text] [Related]
9. Plant-derived hemagglutinin protects ferrets against challenge infection with the A/Indonesia/05/05 strain of avian influenza.
Shoji Y; Bi H; Musiychuk K; Rhee A; Horsey A; Roy G; Green B; Shamloul M; Farrance CE; Taggart B; Mytle N; Ugulava N; Rabindran S; Mett V; Chichester JA; Yusibov V
Vaccine; 2009 Feb; 27(7):1087-92. PubMed ID: 19100806
[TBL] [Abstract][Full Text] [Related]
10. Trends in development of the influenza vaccine with broader cross-protection.
Stropkovská A; Janulíková J; Varecková E
Acta Virol; 2010; 54(1):7-19. PubMed ID: 20201609
[TBL] [Abstract][Full Text] [Related]
11. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age.
Block SL; Yogev R; Hayden FG; Ambrose CS; Zeng W; Walker RE
Vaccine; 2008 Sep; 26(38):4940-6. PubMed ID: 18662737
[TBL] [Abstract][Full Text] [Related]
12. Pandemic preparedness: toward a universal influenza vaccine.
Roose K; Fiers W; Saelens X
Drug News Perspect; 2009 Mar; 22(2):80-92. PubMed ID: 19330167
[TBL] [Abstract][Full Text] [Related]
13. The specificity of serum antibodies to the haemagglutinin of influenza B viruses induced by vaccination.
Creţescu L; Ioniţă E; Niculescu IT; Coban V; Bogdan C
Arch Roum Pathol Exp Microbiol; 1987; 46(1):27-33. PubMed ID: 3324992
[No Abstract] [Full Text] [Related]
14. Promises and challenges of live-attenuated intranasal influenza vaccines across the age spectrum: a review.
Boyce TG; Poland GA
Biomed Pharmacother; 2000 May; 54(4):210-8. PubMed ID: 10872719
[TBL] [Abstract][Full Text] [Related]
15. Live Victoria/75-ts-1[E] influenza A virus vaccines in adult volunteers: role of hemagglutinin immunity in protection against illness and infection caused by influenza A virus.
Douglas RG; Markoff LJ; Murphy BR; Chanock RM; Betts RF; Hayden FG; Levine MM; Van Blerk GA; Sotman SB; Nalin DR
Infect Immun; 1979 Oct; 26(1):274-9. PubMed ID: 500204
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous administration of live, attenuated influenza A vaccines representing different serotypes.
Wright PF; Bhargava M; Johnson PR; Thompson J; Karzon DT
Vaccine; 1985 Sep; 3(3):305-8. PubMed ID: 3904259
[TBL] [Abstract][Full Text] [Related]
17. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
[TBL] [Abstract][Full Text] [Related]
18. Development of cell culture (MDCK) live cold-adapted (CA) attenuated influenza vaccine.
Ghendon YZ; Markushin SG; Akopova II; Koptiaeva IB; Nechaeva EA; Mazurkova LA; Radaeva IF; Kolokoltseva TD
Vaccine; 2005 Sep; 23(38):4678-84. PubMed ID: 16026905
[TBL] [Abstract][Full Text] [Related]
19. [Determination of the quantitative hemagglutinin content in influenza vaccine by means of radial immunodiffusion].
Chubarova NI
Tr Inst Im Pastera; 1979; 52():128-32. PubMed ID: 121647
[No Abstract] [Full Text] [Related]
20. Genetic stability of live, cold-adapted influenza virus components of the FluMist/CAIV-T vaccine throughout the manufacturing process.
Buonagurio DA; Bechert TM; Yang CF; Shutyak L; D'Arco GA; Kazachkov Y; Wang HP; Rojas EA; O'Neill RE; Spaete RR; Coelingh KL; Zamb TJ; Sidhu MS; Udem SA
Vaccine; 2006 Mar; 24(12):2151-60. PubMed ID: 16413951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
